ALK and cancer: As in the cases of EGFR, ALK, and ROS1, the constitutive activation of such targets is the driving cause of a subset of NSCLC and is required for the survival of those cancer cells; therefore, the presence of constitutive activating mutations or gene rearrangement can be explored as predictive biomarkers for patient stratification.